CD274 and Tumor Lysis Syndrome: The 81 TLS cases in the anti-(PD-1)/(PD-L1) group between 2018 and 2020 accounted for 49% of the total cases; atezolizumab, avelumab and durvalumab, and cemiplimab entered the market in 2016, 2017, and 2018, respectively.